Agilent | A - Cash And Equivalent


Agilent reported $1.76B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Abbott USD 4.05B 1.05B Sep/2026
Agilent USD 1.76B 49M Jun/2026
Align Technology USD 1.1B 42.76M Jun/2026
Bio Techne USD 350.04M 85.32M Sep/2026
Bio-Rad Laboratories USD 465.3M 51.7M Sep/2026
Bruker USD 184.9M 51.5M Jun/2026
Charles River Laboratories USD 200.38M 8.36M Sep/2026
Danaher USD 5.68B 1.33B Sep/2026
Dentsply International USD 195M 44M Sep/2026
Edwards Lifesciences USD 3.11B 210.8M Sep/2026
Henry Schein USD 184M 27M Sep/2026
Illumina USD 1.29B 249M Sep/2026
Intuitive Surgical USD 6.8B 1.83B Sep/2026
IQVIA Holdings USD 2.25B 340M Sep/2026
Laboratory Of America USD 261.8M 120M Sep/2026
Mettler Toledo International USD 52.24M 854K Sep/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
OraSure Technologies USD 160.58M 16.38M Jun/2026
Quest Diagnostics USD 797M 171M Sep/2026
Quidel USD 166.4M 43M Sep/2026
Repligen USD 726.96M 120.18M Sep/2026
Revvity USD 592.8M 430.14M Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Thermo Fisher Scientific USD 5.46B 1.4B Sep/2026
Waters USD 593M 54M Sep/2026
Zimmer Biomet Holdings USD 399.9M 10.1M Sep/2026